Results(4597)
DARWIN EU® Effectiveness of Human Papillomavirus Vaccines (HPV) to prevent cervical cancer
Norway
Spain
United Kingdom
EU PAS number:
EUPAS1000000080
First published:
02/03/2026
Study
Finalised
The Office for Rare Conditions Registries (ORC Registries)
United Kingdom
First published:
02/03/2026
Institution
Educational Institution
Non EU Institution/Body/Agency
Non-Pharmaceutical company
ENCePP partner
University of Pécs Clinical Centre (UPCC)
Hungary
First published:
02/03/2026
Institution
Hospital/Clinic/Other health care facility
GWT-TUD GmbH - Gesellschaft für Wissens- und Technologietransfer
Germany
First published:
02/03/2026
Institution
Non-Pharmaceutical company
The Danish Multiple Sclerosis Registry (DMSR), Rigshospitalet - Copenhagen University Hospital
Denmark
First published:
02/03/2026
Institution
Educational Institution
Hospital/Clinic/Other health care facility
A Prospective Active Surveillance Study to Monitor Growth, Development, and Maturation Among Adolescents with Atopic Dermatitis Exposed to Abrocitinib (B7451120)
Canada
European Union
United States
EU PAS number:
EUPAS1000000515
First published:
02/03/2026
Study
Ongoing
Incidence and risk factors of losartan-associated anemia
Denmark
EU PAS number:
EUPAS1000000937
First published:
02/03/2026
Study
Planned
Comparing Weight Gain on F/TAF and Placebo Using DISCOVER and iPrEx Study Data
Austria
Brazil
Canada
Denmark
Ecuador
France
Germany
Ireland
Italy
Netherlands
Peru
South Africa
Spain
Thailand
United Kingdom
United States
EU PAS number:
EUPAS1000000509
First published:
02/03/2026
Study
Ongoing
Long-term International Dual-Source Endometriosis and Adenomyosis Registry (LIDEA Registry)
France
Germany
Italy
Spain
United Kingdom
United States
EU PAS number:
EUPAS107377
First published:
02/03/2026
Study
Ongoing
Cross-sectional Study Evaluating the Effectiveness of Venetoclax Risk-Minimisation Measures Among Haematologists in Europe
France
Germany
Poland
Spain
United Kingdom
EU PAS number:
EUPAS104737
First published:
25/02/2026
Study
Finalised
Pfizer Registry of Outcomes in Growth Hormone RESearch (PROGRES) 2.0: A multi-country non-interventional, observational, retrospective cohort study among participants treated with human growth hormone (hGH) treatments Genotropin (somatropin) and Ngenla (somatrogon) under routine clinical care.
Armenia
Belgium
Brazil
Bulgaria
China
Czechia
France
Georgia
Germany
Hong Kong
Italy
Malaysia
Poland
Portugal
Saudi Arabia
Slovenia
Sri Lanka
United Kingdom
United States
EU PAS number:
EUPAS1000000705
First published:
20/02/2026
Study
Ongoing
Belzutifan special drug use results survey in von Hippel-Lindau (VHL) disease-associated tumors: a post-authorization safety study (PASS) (MK-6482-046)
Japan
EU PAS number:
EUPAS1000000881
First published:
20/02/2026
Study
Planned
Belzutifan special drug use results survey in radically unresectable or metastatic renal cell carcinoma: a postauthorization safety study (PASS) (MK-6482-045)
Japan
EU PAS number:
EUPAS1000000880
First published:
20/02/2026
Study
Planned
Matching-Adjusted Indirect Treatment Comparison of Sotorasib vs Adagrasib for Previously Treated Non-Small Cell Lung Cancer with KRAS G12C Mutation (20240246)
United States
EU PAS number:
EUPAS1000000380
First published:
20/02/2026
Study
Finalised
Dutch Pregnancy Drug Register
First published:
19/02/2026
Netherlands
Data source
Human
OtherRecord completeness: 100%
A Non-Interventional Study (NIS) PASS to characterize secondary malignancies of T-cell origin following tisagenlecleucel therapy (CCTL019B2402)
Australia
Austria
Brazil
Canada
Czechia
France
Germany
Hong Kong
Israel
Italy
Japan
Korea, Republic of
Netherlands
Poland
Russian Federation
Saudi Arabia
Singapore
Spain
Switzerland
Taiwan
United Kingdom
United States
EU PAS number:
EUPAS1000000749
First published:
19/02/2026
Study
Planned
Big Multiple Sclerosis Data (BMSD) Network
Australia
Czechia
Denmark
France
Germany
Italy
Sweden
First published:
19/02/2026
Network
Oral and Long-Acting Injectable Cabotegravir Preexposure Prophylaxis Use Among U.S. Veterans Using Veterans Health Administration Services, 2021-2025 (306339)
United States
EU PAS number:
EUPAS1000000939
First published:
19/02/2026
Study
Planned
Unidade Local de Saúde de Matosinhos
First published:
19/02/2026
Portugal
Data source
Human
Administrative healthcare records (e.g., claims)
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Pharmacy dispensing records
Primary care medical records
Specialist ambulatory care recordsRecord completeness: 93%
Vyepti Pregnancy Registry: A prospective, comparative cohort study of maternal, fetal and infant safety in pregnant women exposed to eptinezumab in the United States
United States
EU PAS number:
EUPAS1000000936
First published:
19/02/2026
Study
Ongoing
Non-Interventional Postmarketing Safety Study of the COMIRNATY 2025-2026 Formula (LP.8.1) in the United States
United States
EU PAS number:
EUPAS1000000932
First published:
19/02/2026
Study
Planned
Comparative Study: Long-Term Neurodevelopmental Outcomes in Neonates Treated with Lacosamide vs Other Antiseizure Medications for Neonatal Seizures
United States
EU PAS number:
EUPAS1000000618
First published:
19/02/2026
Study
Finalised
ARCA Cardiology
First published:
19/02/2026
Italy
Data source
Human
Hospital inpatient records
Hospital outpatient visit records
OtherRecord completeness: 85%
InGef Research Database
First published:
19/02/2026
Germany
Data source
Human
Administrative healthcare records (e.g., claims)Record completeness: 93%
Pregnancy, fetal and infant outcomes of pregnancies exposed to eptinezumab compared to two migraine control cohorts unexposed to eptinezumab: a claims database study in the United States
United States
EU PAS number:
EUPAS1000000938
First published:
18/02/2026
Study
Ongoing
Effectiveness Evaluation of PALFORZIA Risk Management Plan Educational Materials
France
Germany
United Kingdom
EU PAS number:
EUPAS40247
First published:
18/02/2026
Study
Ongoing
Real World Use, Effectiveness and Safety of Teprotumumab among Thyroid Eye Disease Patients treated in China BOAO Pilot Zone: A Retrospective Cohort Study (20240345)
China
EU PAS number:
EUPAS1000000625
First published:
18/02/2026
Study
Ongoing
Actionable Real-world evidence network
First published:
18/02/2026
Netherlands
Spain
United Kingdom
Data source
Human
Administrative healthcare records (e.g., claims)
Disease registry
Pharmacy dispensing recordsRecord completeness: 76%
Post-authorization observational study on the use of QUVIVIQ in standard clinical setting for the treatment of Chronic Insomnia in France
France
EU PAS number:
EUPAS1000000363
First published:
18/02/2026
Study
Ongoing
Immune Mediated Inflammatory Disease (IMID) Observatory
First published:
18/02/2026
Finland
France
Germany
Netherlands
Spain
Sweden
United Kingdom
Data source
Human
Administrative healthcare records (e.g., claims)
Diagnostic tests or procedures reimbursement
Disease registry
Drug registry
Emergency care discharge records
Hospital discharge records
Hospital inpatient records
Hospital outpatient visit records
Other
Pharmacy dispensing records
Population registry
Registration with healthcare system
Specialist ambulatory care records
Spontaneous reports of suspected adverse drug reactionsRecord completeness: 52%
ReMuS Registry / ReMuS, The Czech Republic Multiple Sclerosis Patient Registry / ReMuS, Registr pacientů s roztroušenou sklerózou
First published:
18/02/2026
Czechia
Data source
Human
Disease registryRecord completeness: 85%
The Danish Multiple Sclerosis Registry
First published:
17/02/2026
Denmark
Data source
Human
Disease registryRecord completeness: 59%
EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE
Denmark
France
Germany
Italy
Netherlands
Spain
United Kingdom
EU PAS number:
EUPAS36005
First published:
17/02/2026
Study
Finalised
General Use-results Survey of IMDELLTRA in Patients with Small Cell Lung Cancer Progressed after Cancer Chemotherapy (20230313)
Japan
EU PAS number:
EUPAS1000000817
First published:
17/02/2026
Study
Planned
Post Conditional Approval Active Surveillance Study Among Individuals in Europe Receiving the Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine
Italy
Netherlands
Norway
Spain
United Kingdom
EU PAS number:
EUPAS41623
First published:
17/02/2026
Study
Ongoing
Comparative effectiveness and safety of omalizumab and dupilumab in children with asthma
Korea, Republic of
EU PAS number:
EUPAS1000000361
First published:
16/02/2026
Study
Ongoing
DARWIN EU® - Capturing obesity in DARWIN EU
Belgium
Croatia
Denmark
France
Germany
Greece
Netherlands
Portugal
Spain
EU PAS number:
EUPAS1000000820
First published:
16/02/2026
Study
Planned
Periodic Knowledge, Attitudes, and Behavior (KAB) Survey of Certified Prescribers to Assess Understanding of the Risks with the BKEMV™ Risk Evaluation and Mitigation Strategy (REMS) (20240216)
United States
EU PAS number:
EUPAS1000000367
First published:
16/02/2026
Study
Ongoing
A prospective multicenter observational post authorization safety sub-registry to characterize the long-term safety profile of commercial use of eliglustat (Cerdelga®) in adult patients with Gaucher disease (ELISAFE)
Belgium
Denmark
Greece
Italy
Portugal
Romania
Spain
United Kingdom
EU PAS number:
EUPAS11998
First published:
16/02/2026
Study
Finalised
Compare data sources